Materialise NV: Third Quarter 2024 Financial Summary
Business Context and Reporting Period
This Form 6-K filing reports the unaudited financial results for Materialise NV for the third quarter ended September 30, 2024. Materialise is a global provider of 3D printing software and services, operating through three primary segments: Materialise Medical, Materialise Software, and Materialise Manufacturing.
Key Financial Metrics
| Metric (in '000 EUR) | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Total Revenue | 68,652 | 60,130 | +14.2% |
| Gross Profit | 39,297 | 33,696 | +16.6% |
| Gross Margin | 57.2% | 56.0% | +120 bps |
| Operating Profit | 4,313 | 2,330 | +85.1% |
| Net Profit | 3,038 | 4,013 | -24.3% |
| Adjusted EBIT | 4,408 | 2,330 | +89.2% |
| Adjusted EBITDA | 9,895 | 7,857 | +25.9% |
| Cash & Equivalents | 116,163 | 127,573 | -8.9% |
| Gross Debt | 53,037 | 64,398 | -17.6% |
| Net Cash Position | 63,126 | 63,175 | -0.1% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 14.2% year-over-year. The Medical segment led growth with a 24.5% increase to €30.2M. The Manufacturing segment grew 9.1% to €27.3M, while Software grew modestly by 2.8% to €11.1M.
- Profitability: Operating profit nearly doubled to €4.3M, driven by improved gross margins and controlled operating expenses. However, Net Profit declined to €3.0M from €4.0M due to a shift in the net financial result from a gain of €1.3M in 2023 to a loss of €1.1M in 2024, primarily attributed to unfavorable currency exchange effects.
- Segment Performance: Adjusted EBITDA margins improved in Medical (32.8% vs 29.4%) and Software (17.8% vs 16.5%). Conversely, the Manufacturing segment saw its Adjusted EBITDA margin contract to 2.6% from 4.3%.
- Liquidity: The company maintained a stable net cash position of approximately €63.1M, despite a reduction in gross debt of over €11M. Operating cash flow for the quarter was €6.9M, down from €8.1M in the prior year.
Outlook, Risks, and Unusual Items
- Currency Impact: Management highlighted unfavorable currency exchange effects as a primary driver for the decline in net financial results and net profit compared to the prior year.
- Capital Expenditures: Total capital expenditures for the quarter were €7.3M, indicating continued investment in property, plant, and equipment.
- Non-IFRS Measures: The filing emphasizes Adjusted EBIT and Adjusted EBITDA as key performance indicators, excluding share-based compensation and acquisition-related expenses (specifically related to the Feops acquisition).
- Guidance: The filing text does not provide specific forward-looking financial guidance or revenue targets for the full year 2024 or 2025.
Investor Verification Checklist
- Verify the specific impact of currency exchange rates on the net financial result and future quarters.
- Review the drivers behind the margin compression in the Materialise Manufacturing segment.
- Assess the sustainability of the 24.5% revenue growth in the Medical segment.
- Confirm the timeline and integration status of the Feops acquisition expenses.
- Monitor the trend in operating cash flow, which decreased year-over-year despite revenue growth.